Whole Pharmacogenomics Scan (WPS)

DNA strand for Precision Medicine

Whole Pharmacogenomics Scan (WPS)

Make precision medicine part of your practice

Elevate Standard of Care with Preemptive Pharmacogenomics (PGx) Testing

Whole Pharmacogenomics Scan (WPSTM) is the most comprehensive, customizable, and scalable preemptive PGx test which can analyze nearly all actionable pharmacogenetic genes of a patient with a single, one-time test.1

Download WPS brochure

View WPS gene list or search the gene or drug of interests.

KEY ADVANTAGES

COMPREHENSIVE

Multiple genes may affect the response of a drug and each gene/drug combination has a different level of evidence and actionability.

We guide our customers to integrate the correct level of PGx information that meets their system’s needs and provides actionable clinical value to their patients.

WPS: 

  • Provides deep coverage of genetic variants, including many rare alleles that are not identified by most other assays with analysis of duplications/deletions, complex structural arrangements, and copy number information.
  • Leads to more accurate and precise genotyping/ phenotyping of each PGx gene, including complex genes, such as CYP2D6
  • Enables the detection of many rare genotypes which is critical when diagnosing patients from diverse populations

SCALABLE

WPS customers can build their unique precision medicine program by beginning with one or multiple medical conditions or focusing on a particular group of patients. WPS knowledge base can be expanded to meet additional medical conditions and patient groups as the program grows.

By creating a patient’s PGx database, WPS enables continuous re-analysis of a patient’s PGx profile and updates clinical recommendations as new clinical guidelines and evidence become available to guide choice of medications and dosing.

CUSTOMIZABLE

Customers can choose the genes/drugs combinations that provide the best value to their patients with WPS four-tier system.

We work closely with each customer to create a customized clinical report that best aligns with their medical practice and also adjust the clinical report as their teams and practices evolve.

Instituting WPS preemptive testing

  • Allows patient’s PGx profile to be available before clinical decisions are made regarding future medications
  • Informs potentially life-threatening decisions regarding best treatment options
  • Is cost effective since one test can potentially meet a patient’s life-long PGx needs
Doctors meeting about Standard Of Care

WPS CLINICAL REPORTS

Test results come in two reports:

  • Comprehensive PGx report based on patient’s WPS profile.
  • Individualized and actionable clinical recommendations based on the patient’s WPS profile and medication list.*

Download Sample Reports

WPS sample report

Key Features
Actionable

Gene/drug pairs categorized based on levels of actionability and evidence.

Individualized

Use individual’s genomic profile and medication history to potentially fulfill individual’s life-long PGx needs.

Customizable

Select the desired gene/drug pairs that work the best for each clinical practice.

Evidence-based

Use clinical evidence curated by the experts at RPRD, from CPIC guidelines6 , FDA label informationand other peer-reviewed scientific studies.8

EMR Integration

Work with customers toward EMR data integration and clinical decision support.

Case example

A leading U.S. pediatric hospital:

  • Utilizing preemptive PGx for patient care using WPS and its predecessor since 20119,10
  • Nearly 4,500 patients have benefited from the program as of November 201811

Keys To Successful WPS Implementation9

  • Get institutional support
  • Partner with a knowledgable clinical laboratory
  • Develop a process to manage any incidental findings
  • Develop a strategy to educate clinicians and patients
  • Develop a process to return results
  • Extensive use of informatics, especially clinical decision support, integrated to EHR
Keys to Implementing WPS

WPS gene/drug pairs with Clinical Evidence

Would you like to find out what genes are included in the WPS testing? Please search the gene or drug of interest using our WPS gene/drug evidence database.

References
  1. WPS solution is based on the PharmacoScanTM assay
  2. Clinical Pharmacogenetics Implementation Consortium (CPIC®)
  3. Relling MV, et al. Pharmacogenomics in the Clinic. Nature. 2015 Oct;526(7573):343-50.
  4. Ji Y, et al. Preemptive Pharmacogenomic Testing for Precision Medicine: A Comprehensive Analysis of Five Actionable Pharmacogenomic Genes Using Next-Generation DNA Sequencing and a Customized CYP2D6 Genotyping Cascade. J Mol. Diagn. 2016 May;18(3):438-46.
  5. Dunnenberger HM, et al. Preemptive Clinical Pharmacogenetics Implementation: Current Programs in Five US Medical Centers. Annu Rev Pharmacol Toxicol. 2015 Jan;55:89-106.
  6. Clinical Pharmacogenetics Implementation Consortium (CPIC®) 
  7. Table of Pharmacogenomic Biomarkers in Drug Labeling 
  8. Pharmacogenomics Knowledge Base (PharmGKB) 
  9. Hoffman JM, et al. PG4KDS: a Model for the Clinical Implementation of Pre-emptive Pharmacogenetics. Am J Med Genet C Semin Med Genet. 2014 Mar;166C(1):45-55.
  10. https://www.prnewswire.com/news-releases/rprd-diagnostics-partners-with-st-jude-childrens-research-hospital-to-offer-comprehensive-pharmacogenetics-testing-300539615.html 
  11. PG4KDS: Clinical Implementation of Pharmacogenetics.

 

*Individualized clinical reports are available when the electronic version of the patient’s medication list is provided.